NeuroDiagnostics (“NDx”) has the only minimally invasive highly accurate test, DISCERN™, for Alzheimer’s Disease.
Multidisciplinary teams at the NIH and the Rockefeller Neurosciences Institute, led by Dr. Alkon, over the last 30 years led to the development of the three biomarkers. The three biomarkers comprise an AD-Index assay, a Morphometric Imaging assay, and a PKC Epsilon assay.
FDA has granted NDx Breakthrough Status. Our diagnostic biomarkers have been confirmed by autopsy validation (NIH “Gold Standard”).